A therapeutic trial with calcium channel antagonist nifedipine did not lead to a significant increase in plasma glucose or decrease in plasma insulin after a single administration of 0.2 mg/kg nifedipine, nor an improvement in hypoglycemia rate or fasting tolerance during 7 days of administration (1 mg/kg/d of extended-release nifedipine). This evidence concerns the gene INS and Hypoglycemia.